Results 61 to 70 of about 12,566 (192)

Obesity management: Update on orlistat

, 2008
Belinda S Drew, Andrew F Dixon, John B DixonCentre for Obesity Research and Education, Monash University, Melbourne, AustraliaAbstract: Over the past 20 years obesity has become a worldwide concern of frightening proportion. The World Health Organization
Andrew F Dixon, John B Dixon, Belinda S Drew   +2 more
core  

Does orlistat cause acute kidney injury?

, 2011
Orlistat is an inhibitor of gastric and pancreatic lipase with proven efficacy in the augmentation and maintenance of weight loss. Although its use has been limited by troublesome but benign gastrointestinal side effects, it has more recently been ...
Amit X. Garg, Michael M. Beyea, Matthew A. Weir   +2 more
core   +1 more source

ORLISTAT : Kan orlistat ha andra hälsoeffekter i kroppen förutom viktminskningseffekten?

, 2017
Bakgrund: I dagens samhälle med en kombination av allt mer stillasittande livsstil och tillgång till ett brett utbud av kaloririka livsmedel har det lett till en global epidemi av övervikt och fetma som är en riskfaktor för många sjukdomar.
Mohammadshahi, Faisal
core   +2 more sources

Investigating the Hepatic Response to Orlistat and White Tea in Rats on a High-Fat Diet

Life
High-fat diets have detrimental health impacts that increase the likelihood of developing obesity and metabolic syndrome. This study aimed to examine the potential antioxidant and anti-inflammatory effects of orlistat and white tea in rats fed a high-fat
Serpil Ciftel, Aleksandra Klisic, Enver Ciftel, Tolga Mercantepe, Adnan Yilmaz, Sedat Ciftel, Esra Pinarbas, Merve Nur Toraman, Filiz Mercantepe   +8 more
doaj   +1 more source

Orlistat after initial dietary/behavioural treatment: changes in body weight and dietary maintenance in subjects with sleep related breathing disorders

Nutrition Journal, 2011
Background Sleep related breathing disorders (SRBD) are associated with increased morbidity and mortality and weight loss is recommended to overweight or obese patients with SRBD. However, maintenance of weight loss is difficult to achieve and strategies
Tonstad Serena, Svendsen Mette
doaj   +1 more source

Exploring lifestyle management in polycystic ovary syndrome through implementation frameworks

Experimental Physiology, EarlyView.
Abstract Polyendocrine metabolic ovarian syndrome [PMOS; previously known as polycystic ovary syndrome (PCOS)] is an endocrine condition affecting 10%–13% of women of reproductive age, with cardiometabolic, reproductive and psychological features. The PMOS guidelines have established recommendations for its management, which can include pharmacological,
Margaret McGowan, Stephanie Cowan, Chau Thien Tay, Lisa J. Moran, Ashley H. Ng   +4 more
wiley   +1 more source

Oral aphthous ulcers associated with orlistat

, 2016
Orlistat, a reversible inhibitor of gastrointestinal lipase, is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet.
Sheikh-Taha, Marwan
core   +1 more source

Update of Korean Medicine Clinical Practice Guidelines for Obesity Management: An Evidence‐Based GRADE Approach

Obesity, Volume 34, Issue 11, Page 2031-2050, November 2026.
ABSTRACT Objective Obesity is a major health challenge associated with multiple chronic diseases. Korean traditional medicine (KM) offers diverse therapeutic approaches for obesity management. This study aims to update the Korean Medicine Clinical Practice Guidelines (KMCPGs) by incorporating recent evidence to improve the effectiveness of KM‐based ...
Soo‐Dam Kim, Mi Ju Son, Bo‐Young Kim, Mi Mi Ko, Kyung Hwan Jegal, Hojun Kim, Seo‐Hyun Park, Koh‐Woon Kim, Mi Young Song, Junyoung Jo, Hyungsuk Kim, Woo‐Chul Shin, Taeoh Kim, HuiYan Zhao, Changsop Yang, Won‐Seok Chung, Sungha Kim   +16 more
wiley   +1 more source

Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients [PDF]

, 2010
To evaluate the effects of 1-year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and inflammatory parameters in obese type 2 diabetic patients.
Cicero AF, I. Palumbo, FERRARI, ILARIA, Palumbo I, G. Derosa, Sabrina Randazzo, Arrigo F.G. Cicero, Angela D’Angelo, D'ANGELO, ANGELA, DEROSA, GIUSEPPE, Ilaria Palumbo, Ilaria Ferrari, CICERO, ARRIGO FRANCESCO GIUSEPPE, I. Ferrari, Pamela Maffioli, FOGARI, ELENA, P. Maffioli, Giuseppe Derosa, A. D'Angelo, MAFFIOLI, PAMELA, Randazzo S, E. Fogari, Elena Fogari, S. Randazzo   +23 more
core   +1 more source

Semaglutide and Panic Attacks: Active‐Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post‐Marketing Pharmacovigilance

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Purpose To evaluate how confounding by indication and notoriety bias shape the apparent semaglutide–panic attack signal in the FDA Adverse Event Reporting System (FAERS) and to interpret this signal using an evidence‐triangulation framework integrating randomized and observational studies.
Ben Melamed, Mahak Parsi‐Zahabi, Mohammad Ali Omrani, Bala Swetha Baskaran, Lujain Ez Eddin, Nazgol Kermanshahi, Niaz Chalabianloo, Flory Tsobo Muanda   +7 more
wiley   +1 more source